TIME named Guardant Health, Inc. co-CEOs Helmy Eltoukhy and AmirAli Talasaz to its 2025 TIME100 Health list, recognizing them among the 100 most influential people in global health. This honor acknowledges their leadership and the company's impact in transforming cancer care.
AmirAli Talasaz emphasized that this inclusion recognizes the technology built by the Guardant team, particularly the Shield blood test for colorectal cancer, and its potential to save lives globally. The Shield test, a result of over 10 years of R&D, aims to detect multiple cancers at an early stage.
Helmy Eltoukhy stated that this recognition is a testament to their mission to conquer cancer with data, changing lives by enabling earlier detection and faster treatment selection. The company's blood tests aim to replace invasive biopsies and provide more insights from cancer data, potentially lowering the total cost of care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.